Should You Buy Clearpoint Neuro Inc (CLPT) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Buy
Latest Price
12.930
1 Day change
-3.65%
52 Week Range
30.100
Analysis Updated At
2026/01/28
Buy (starter position now). For a beginner long-term investor with $50k–$100k who doesn’t want to wait, CLPT is attractive at the current ~$13.62 because it’s pulling back toward key support while fundamentals/news flow are improving (EU MDR certification + guided Q4’25 revenue growth). Short-term technicals are weak, so the cleanest approach is to start with a partial buy now and add if it holds the ~$13.0–$13.7 support zone.
Technical Analysis
Trend/price action: CLPT is down ~4.9% today to ~$13.62, sitting just below S1 (~13.688) and well below the pivot (~14.83), which suggests near-term downside pressure but also that it’s near a logical support area.
Momentum: MACD histogram is negative (-0.0518) and expanding bearishly, indicating weakening momentum.
RSI: RSI(6) ~39.2 (neutral-to-weak), consistent with a pullback that’s not yet deeply oversold.
Moving averages: Converging MAs suggest consolidation/indecision rather than a clean uptrend.
Levels to watch: Support = ~13.69 then ~12.98; Resistance = ~14.83 (pivot) then ~15.97.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Bottom line (technical): Short-term trend is soft, but price is nearing support where a long-term entry can be reasonable if you’re willing to add on confirmation (reclaiming ~14.83).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Both put-call ratios are very low (OI PCR 0.25; Volume PCR 0.12), which is typically bullish positioning (more calls than puts).
Activity/positioning: Today’s option volume is elevated vs the 30-day average (~28.6x), signaling increased attention/speculation.
Volatility: IV is extremely high (30D IV ~97.8; HV ~110.4; IV percentile ~80). This implies the market expects big moves; sentiment leans bullish, but the stock can swing sharply.
Technical Summary
Sell
10
Buy
6
Positive Catalysts
Regulatory/market access: ClearPoint Navigation Software v3.0.2 received EU MDR certification (supports international commercialization and adoption).
Growth outlook: Company expects ~ $10.4M revenue for Q4 2025, ~20% YoY growth.
Segment momentum: Reported 23% growth in functional neurosurgery disposables and 26% growth in biologics, with continued growth anticipated into
Pattern-based trend model: Similar-candlestick study suggests upside skew over the next month (referenced ~13.88% next-month move in the dataset).
Neutral/Negative Catalysts
Short-term technical weakness: Bearish MACD and price below pivot increases risk of further drift toward ~13.0 support.
High-volatility profile: Extremely high IV/HV indicates unstable pricing and sharp drawdowns can occur even on good news.
Profitability not reached: Latest quarter still shows a net loss (improving, but negative).
News feed noise: Part of the provided news mentions Booz Allen Hamilton (not CLPT), which reduces signal quality from the news set and suggests investors should focus only on CLPT-specific releases.
Financial Performance
Latest quarter provided: 2025/Q3.
- Revenue: $8.861M, +9.10% YoY (steady growth).
- Net income: -$5.891M (loss), improved 18.44% YoY (loss narrowing).
- EPS: -$0.21, improved 16.67% YoY.
- Gross margin: 63.2%, +5.90% YoY (notable margin improvement).
Overall: Growth + improving margins support a long-term thesis, but the company remains loss-making, which contributes to volatility.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target trend data was provided in the dataset, so changes in consensus can’t be confirmed here.
Wall Street-style pro view (based on provided fundamentals/news): improving revenue trajectory, strong gross margin, expanding disposables/biologics, and EU MDR certification as a catalyst.
Con view: still unprofitable with high volatility and a choppy technical setup, which can pressure sentiment during market pullbacks.
Influential/politician activity: No recent congress trading data available; hedge fund and insider trading trends are reported as neutral with no significant recent activity.
Wall Street analysts forecast CLPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLPT is 29 USD with a low forecast of 28 USD and a high forecast of 30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CLPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLPT is 29 USD with a low forecast of 28 USD and a high forecast of 30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.420
Low
28
Averages
29
High
30
Current: 13.420
Low
28
Averages
29
High
30
B. Riley
Buy
maintain
$20 -> $28
AI Analysis
2025-04-25
Reason
B. Riley
Price Target
$20 -> $28
AI Analysis
2025-04-25
maintain
Buy
Reason
B. Riley raised the firm's price target on ClearPoint Neuro to $28 from $20 and keeps a Buy rating on the shares following a transfer of coverage. ClearPoint is a medical device company focused on providing image-guided navigation for minimally invasive neuro procedures, the analyst tells investors in a research note. The firm says the company's core business continues to grow over 20% annually, and that it expects significant growth in the future as biopharma partnerships progress towards regulatory approvals and commercial launches.
